Methodological recommendations of the Regulatory Agencies;Recomendaciones metodológicas de las agencias reguladoras

Medicina Clinica

Volumn 125, Issue SUPPL. 1, 2005, Pages 72-76

  Torres, Ferran ^a,b   Calvo, Gonzalo ^b,c   Pontes, Caridad ^d  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c Agencia Española de Medicamentos Y Productos Sanitarios AEMPS   (Spain)

^d Departamento Médico   (Spain)

Author keywords

Clinical trials; Methodological issues; Regulatory guidelines; Statistical issues

Indexed keywords

ARTICLE; CLINICAL TRIAL; HEALTH CARE PERSONNEL; INTERNET; MEDICAL LITERATURE; MEDICAL RESEARCH; PRACTICE GUIDELINE; PUBLICATION;

BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; DRUG EVALUATION; DRUG EVALUATION, PRECLINICAL; EUROPE; GOVERNMENT AGENCIES; GUIDELINES AS TOPIC; MULTICENTER STUDIES AS TOPIC; PUBLISHING; RESEARCH DESIGN; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 34547725155     PISSN: 00257753     EISSN: 15788989     Source Type: Journal    
DOI: 10.1016/s0025-7753(05)72213-2     Document Type: Article

References (14)

1. International Conference on Harmonization (ICH). ICH Harmonised Tripartite Guideline Topic E3: Structure and Content of Clinical Study Reports. November, 1995.
2. International Conference on Harmonization (ICH). ICH Harmonised Tripartite Guideline Topic E6: Good Clinical Practice. June, 1996.
3. International Conference on Harmonization (ICH). ICH Harmonised Tripartite Guideline Topic E9: Statistical Principles for Clinical Trials. February, 1998.
4. International Conference on Harmonization (ICH). ICH Harmonised Tripartite Guideline Topic E10: Choice of Control Group and Related Issues in Clinical Trials. July, 2000.
5. Committee for Proprietary Medicinal Products (CPMP). CPMP/EWP/482/99 Final. Points to consider on switching between superiority and non-inferiority. London: European Medicines Agency; July, 2000.
6. Committee for Proprietary Medicinal Products (CPMP). CPMP/EWP/2330/99 Final. Points to Consider on Application with 1.) Meta-analyses and 2.) One Pivotal study. London: European Agency for the Evaluation of Medicinal Product; May, 2001.
7. Committee for Proprietary Medicinal Products (CPMP). CPMP/EWP/1776/99 Final. Points to Consider on Missing Data. London: European Agency for the Evaluation of Medicinal Product; November, 2001.
8. Committee for Proprietary Medicinal Products (CPMP). CPMP/EWP/908/99 Final. CPMP Points to Consider on Multiplicity issues in Clinical Trials. London: European Agency for the Evaluation of Medicinal Product; September, 2002.
9. Committee for Proprietary Medicinal Products (CPMP). CPMP/EWP/2863/99 Final. Points to Consider on Adjustment for baseline Covariates. London: European Agency for the Evaluation of Medicinal Product; May, 2003.
10. Committee for Proprietary Medicinal Products (CPMP). EMEA/CPMP/EWP/2158/ 99 Final. Guideline on the choice of the non-inferiority margin. London: European Medicines Agency; July 27, 2005.
11. Committee for Medicinal Products for Human Use (CHMP). CHMP/EWP/83561/2005. Guideline on Clinical Trials on Small Populations. London: European Agency for the Evaluation of Medicinal Product; March, 2005.
12. Committee for Proprietary Medicinal Products (CPMP). CPMP/EWP/2459/02. Concept Paper on the Development of a Committee for Propietary Medicinal Products (CPMP) Points to Consider on Methodological Issues in Confirmatory Clinical Trials with Flexible Design and Analysis Plan. London: European Agency for the Evaluation of Medicinal Product; July, 2002.
13. Committee for Medicinal Products for Human Use (CHMP). CHMP/EWP/5872/03. Guideline on Data Monitoring Committees. London: European Agency for the Evaluation of Medicinal Product; July, 2005.
14. Committee for Proprietary Medicinal Products (CPMP). CPMP/EWP/139391/04 Draft. Reflection Paper on the regulatory guidance for the use of Health-Related Quality of Life (HRQL) measures in the evaluation of medicinal products. London: European Agency for the Evaluation of Medicinal Product; November, 2004.